Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients. Here, outcomes from ZUMA-5 are compared with the international...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghione, Paola, Palomba, M. Lia, Patel, Anik R., Bobillo, Sabela, Deighton, Kevin, Jacobson, Caron A., Nahas, Myrna, Hatswell, Anthony J., Jung, A. Scott, Kanters, Steve, Snider, Julia Thornton, Neelapu, Sattva S., Ribeiro, Maria Teresa, Brookhart, M. Alan, Ghesquieres, Herve, Radford, John, Gribben, John G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Gene Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412012/
https://www.ncbi.nlm.nih.gov/pubmed/35679476
http://dx.doi.org/10.1182/blood.2021014375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412012/
https://www.ncbi.nlm.nih.gov/pubmed/35679476
http://dx.doi.org/10.1182/blood.2021014375

Ejemplares similares